YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
CVRx CVRX announced that Devoted Health has issued a Medicare Advantage coverage policy for its Barostim therapy, effective July 17, 2026. The policy covers patients under the current FDA-approved indication and those enrolled in the BENEF…
(RTTNews) - CVRx, Inc. (CVRX), a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease, announced financial results for the second quarter of 2026. Revenue for Q2 2026 was $15.7 million, up…
CVRx, Inc. MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patie…
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca…
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca…
CVRx CVRX shares rallied 11.6% in the last trading session to close at $5.86. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.8% loss ove…
CVRx Inc. CVRX announced a key reimbursement win after Humana issued a Medicare Advantage coverage policy for its Barostim therapy. The development marks an important step in expanding patient access and supporting broader adoption of the…
CVRx, Inc. MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patien…
CVRx logo Key Points Interested in CVRx, Inc.? Here are five stocks we like better. CVRx topped first-quarter expectations with revenue of $14.8 million, up 20% year over year, driven mainly by a 22% increase in U.S. revenue from its Baros…
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, toda…
* CVRx (CVRX [https://seekingalpha.com/symbol/CVRX]) on Monday said total revenue for the first quarter of 2026 is expected to be in the range of $14.7 million to $14.8 million compared to revenue for the first quarter of 2025 of $12.3 mil…
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com…
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com…
Earnings Call Insights: CVRx (CVRX) Q4 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, highlighted fourth quarter revenue of $16 million and full year revenue of $56.7 million, noting "growth of 4% and 10%, respectively." Hykes desc…
Image source: The Motley Fool. Date Thursday, Feb. 12, 2026 at 4:30 p.m. ET Call participants President and Chief Executive Officer — Kevin Hykes Chief Financial Officer — Jared Oasheim Full Conference Call Transcript Kevin Hykes. Thanks,…
CVRx (CVRX) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly…
[Weekly report and stack of papers.] designer491 Financials, information technology, and consumer discretionary are set to lead this week’s earnings calendar, with 372 companies scheduled to report. This week’s quant rankings highlight a c…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CVRx (CVRX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in CVRx and would like to discuss you…
Health care stocks declined late Friday afternoon, with the NYSE Health Care Index and the State Str PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca…
(RTTNews) - Several healthcare and medtech stocks staged notable rebounds in after-hours trading Wednesday, with gains driven by updated guidance, margin improvements, and signs of operational resilience despite mixed quarterly results. Rx…
Earnings Call Insights: CVRx, Inc. (CVRX) Q3 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, stated that "Q3 was a strong quarter for CVRx. We grew revenue by double digits year-over-year and expanded our commercial footprint." He e…
CVRx (CVRX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.57 per share a year ago. These figures are adjusted for non-recurring items. This quarterly…
MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca…
Earnings Call Insights: CVRx (CVRX) Q2 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, announced "total revenue of $13.6 million in the second quarter, a 15% increase over the same quarter last year." U.S. Heart Failure revenue was…
* CVRx press release [https://seekingalpha.com/pr/20188110-cvrx-reports-second-quarter-2025-financial-and-operating-results] (NASDAQ:CVRX [https://seekingalpha.com/symbol/CVRX]): Q2 GAAP EPS of -$0.57 misses by $0.05. * Revenue of $13.6M (…
CVRx Inc (NASDAQ:CVRX [https://www.chartmill.com/stock/quote/CVRX/profile]), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, reported its second-quarter 2025 financial result…
The market expects Steris (STE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnin…
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca…
CVRx (CVRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture,…
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with ca…
[doctor working in hospital laboratory] sinology/Moment via Getty Images * CVRx (NASDAQ:CVRX [https://seekingalpha.com/symbol/CVRX]) saw a 17% increase in its shares following the announcement that Centers for Medicare and Medicaid Service…
MINNEAPOLIS - The Centers for Medicare and Medicaid Services (CMS) has proposed to keep CVRx’s Barostim implant procedure in the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,0…
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim impla…
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with car…